Skip to main content
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

660

datasets available to search

ShareScore release 0.9.0

Reset

Dataset results

660 results for “antitumor”

Learn how ShareScore rates datasets ↗
ClinicalTrials.gov32/100

A Study of the Safety and Antitumoral Efficacy of Nivolumab After SIRT for the Treatment of Patients With HCC

ClinicalTrials.gov study NCT03380130. IPD Sharing: NO. Countries: 1. Publications: 9.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov32/100

Clinical Trial of IL - 22BP Safety, Tolerability, and Antitumor Activity in Refractory Solid Tumors.

ClinicalTrials.gov study NCT07040943. IPD Sharing: NO. Countries: 1. Publications: 5.

closedIPD-NOFeb 2026View details →
dryad28/100

Data from: Polycaprolactone nanofibers loaded with 20(S)-Protopanaxadiol for in vitro and vivo antitumor activity study

In this work, 20(S)-Protopanaxadiol (PPD) loaded polycaprolactone (PCL) nanofibers were successfully fabricated by electrospinning technique using tween-80 as a solubilizer. Firstly, smooth and continuous nanofibers were collected by using suitable solvent and appropriate spinning conditions. Secondly, nanofiber mats were characterized by scanning electron microscope (SEM), thermogravimetric (TG) analysis, Fourier transform infrared spectroscopy (FTIR) and mechanical test. Finally, nanofibrous membranes were evaluated using water contact angle, in vitro drug release, biodegradation test, in vitro and vivo antitumor activity and cell apoptosis assay. As a result, scanning electron microscopy observations indicated that diameter of the drug-loaded nanofibers increased with drug concentration increasing. Thermogravimetric (TG) analysis and mechanical test showed nanofibers equipped with great thermal and mechanical properties. Biodegradation test exhibited that the structure of fabricated nanofibers had a certain degree of change after 15 days. In vitro release study showed that PPD from drug-loaded nanofibers could be released in a sustained and prolonged mode. The cytotoxic effect of drug-loaded nanofiber mats examined on the human laryngeal carcinoma cells (Hep-2 cells) demonstrated that the prepared nanofibers had a remarkable antitumor effect. Meanwhile, the drug-loaded fiber mats showed a super antitumor effect in vivo antitumor study. All in all, PCL nanofibers could be a potential carrier of PPD for cancer treatment.

opencc-zeroDec 2017View details →
zenodo28/100

Figure 2 from: Abarova S, Stoitchkova K, Tzonev S, Argirova M, Yancheva D, Anastassova N, Tenchov B (2024) Spectroscopic and thermodynamic characterization of the interaction of a new synthesized antitumor drug candidate 2H4MBBH with human serum albumin. Pharmacia 71: 1-5. https://doi.org/10.3897/pharmacia.71.e112385

Figure 2 Fluorescence titration curve of HSA (4 µM) with the 2H4MBBH in saline at 15 °C and 25 °C. Different curves correspond to 2H4MBBH concentrations of 0, 10, 20, 30, 40, 50 µM, respectively.

opencc-by-4.0Jan 2024View details →
zenodo28/100

Figure 3 from: Abarova S, Stoitchkova K, Tzonev S, Argirova M, Yancheva D, Anastassova N, Tenchov B (2024) Spectroscopic and thermodynamic characterization of the interaction of a new synthesized antitumor drug candidate 2H4MBBH with human serum albumin. Pharmacia 71: 1-5. https://doi.org/10.3897/pharmacia.71.e112385

Figure 3 Stern-Volmer plots for quenching of different 2H4MBBH concentrations (10–50 µM) to HSA (4 µM) in saline at 15 and 25 °C.

opencc-by-4.0Jan 2024View details →
zenodo28/100

Figure 4 from: Mahmod AI, Oqal M, Khalid AM, Afifi FU, Talib WH (2024) Phytochemical analysis, antioxidant, and antitumor activity of Ligustrum ovalifolium leaves grown in Jordan: an in vitro and in vivo study. Pharmacia 71: 1-10. https://doi.org/10.3897/pharmacia.71.e111517

Figure 4 DPPH radical scavenging activity of L. ovalifolium extracts. Ascorbic acid is the positive control in this assay. Results are expressed as means of three independent experiments (bars) ± SEM (lines).

opencc-by-4.0Jan 2024View details →
zenodo28/100

Figure 1 from: Mahmod AI, Oqal M, Khalid AM, Afifi FU, Talib WH (2024) Phytochemical analysis, antioxidant, and antitumor activity of Ligustrum ovalifolium leaves grown in Jordan: an in vitro and in vivo study. Pharmacia 71: 1-10. https://doi.org/10.3897/pharmacia.71.e111517

Figure 1 The antiproliferative activity of L. ovalifolium extracts against (A) T47D cell line (B) MDA-MB-231 cell line (C) HeLa cell line (D) Caco-2 cell line (E) PC3 cell line (F) EMT6/P cell line (G) Fibroblast cell line. Results are expressed as means of three independent experiments (bars) ± SEM (lines).

opencc-by-4.0Jan 2024View details →
zenodo28/100

Supplementary material 1 from: Mahmod AI, Oqal M, Khalid AM, Afifi FU, Talib WH (2024) Phytochemical analysis, antioxidant, and antitumor activity of Ligustrum ovalifolium leaves grown in Jordan: an in vitro and in vivo study. Pharmacia 71: 1-10. https://doi.org/10.3897/pharmacia.71.e111517

Ligustrum ovalifolium leaves ethyl acetate extract LCMS results

opencc-zeroJan 2024View details →
zenodo28/100

Figure 3 from: Mahmod AI, Oqal M, Khalid AM, Afifi FU, Talib WH (2024) Phytochemical analysis, antioxidant, and antitumor activity of Ligustrum ovalifolium leaves grown in Jordan: an in vitro and in vivo study. Pharmacia 71: 1-10. https://doi.org/10.3897/pharmacia.71.e111517

Figure 3 L. ovalifolium ethyl acetate extract effect on tumor size and cure percentage. Compared to the control group, treating tumor-bearing mice with L. ovalifolium has reduced tumor size and improved the cure percentage. (n=9 per group).

opencc-by-4.0Jan 2024View details →
zenodo28/100

Figure 2 from: Mahmod AI, Oqal M, Khalid AM, Afifi FU, Talib WH (2024) Phytochemical analysis, antioxidant, and antitumor activity of Ligustrum ovalifolium leaves grown in Jordan: an in vitro and in vivo study. Pharmacia 71: 1-10. https://doi.org/10.3897/pharmacia.71.e111517

Figure 2 A plot verifying the changes in average tumor size (mm³) vs time (days) of treatment with L. ovalifolium ethyl acetate extract in Balb/C mice inoculated with the EMT6/P cell line.

opencc-by-4.0Jan 2024View details →
zenodo28/100

Figure 6 from: Awajan D, Abu-Humaidan AHA, Talib WH (2024) Study of the antitumor activity of the combination baicalin and epigallocatechin gallate in a murine model of vincristine-resistant breast cancer. Pharmacia 71: 1-20. https://doi.org/10.3897/pharmacia.71.e113446

Figure 6 Anti-proliferation effect of EGCG and baicalin in combination treatment against EMT-6/V different doses of EGCG with a fixed dose of baicalin (70 µM).

opencc-by-4.0Mar 2024View details →
zenodo28/100

Figure 17 from: Awajan D, Abu-Humaidan AHA, Talib WH (2024) Study of the antitumor activity of the combination baicalin and epigallocatechin gallate in a murine model of vincristine-resistant breast cancer. Pharmacia 71: 1-20. https://doi.org/10.3897/pharmacia.71.e113446

Figure 17 Effect of baicalin (75 mg/kg/day), EGCG (50 mg/kg/day), a combination of baicalin and EGCG (75 and 50 mg/kg/day) respectively, vincristine 2 mg/kg/every other day, combination with vincristine (75 and 50 mg/kg/day) for combination and (2 mg/kg/every other day) for vincristine, Positive control (PBS and tween 20%), and healthy group on serum AST average level measured by (IU/L) in EMT-6/P.

opencc-by-4.0Mar 2024View details →
zenodo28/100

Figure 18 from: Awajan D, Abu-Humaidan AHA, Talib WH (2024) Study of the antitumor activity of the combination baicalin and epigallocatechin gallate in a murine model of vincristine-resistant breast cancer. Pharmacia 71: 1-20. https://doi.org/10.3897/pharmacia.71.e113446

Figure 18 Effect of baicalin (75 mg/kg/day), EGCG (50 mg/kg/day), a combination of baicalin and EGCG (75 and 50 mg/kg/day) respectively, vincristine 2 mg/kg/every other day, combination with vincristine (75 and 50 mg/kg/day) for combination and (2 mg/kg/every other day) for vincristine, Positive control (PBS and tween 20%), and healthy group on serum AST average level measured by (IU/L) in EMT-6/V.

opencc-by-4.0Mar 2024View details →
zenodo28/100

Figure 13 from: Awajan D, Abu-Humaidan AHA, Talib WH (2024) Study of the antitumor activity of the combination baicalin and epigallocatechin gallate in a murine model of vincristine-resistant breast cancer. Pharmacia 71: 1-20. https://doi.org/10.3897/pharmacia.71.e113446

Figure 13 The volume change (mm3) for treatment groups in vivo for EMT-6/P and EMT-6/V. Only statistically significant associations are shown. Positive control (PBS and tween 20%), baicalin 75 mg/kg/day, EGCG: 50 mg/kg/day, baicalin and EGCG combination 75 and 50 mg/kg/day respectively, vincristine 2mg/kg/every other day, and same doses were used in the triple therapy.

opencc-by-4.0Mar 2024View details →
zenodo28/100

Figure 22 from: Awajan D, Abu-Humaidan AHA, Talib WH (2024) Study of the antitumor activity of the combination baicalin and epigallocatechin gallate in a murine model of vincristine-resistant breast cancer. Pharmacia 71: 1-20. https://doi.org/10.3897/pharmacia.71.e113446

Figure 22 Effect of baicalin (75 mg/kg/day), EGCG (50 mg/kg/day), a combination of baicalin and EGCG (75 and 50 mg/kg/day) respectively, vincristine 2 mg/kg/every other day, combination with vincristine (75 and 50 mg/kg/day) for combination and (2 mg/kg/every other day) for vincristine, positive control (PBS and tween 20%), and healthy group on average creatinine measured by (mg/dl) in EMT-6/V.

opencc-by-4.0Mar 2024View details →
zenodo28/100

Figure 7 from: Awajan D, Abu-Humaidan AHA, Talib WH (2024) Study of the antitumor activity of the combination baicalin and epigallocatechin gallate in a murine model of vincristine-resistant breast cancer. Pharmacia 71: 1-20. https://doi.org/10.3897/pharmacia.71.e113446

Figure 7 Caspase concentrations in (ng/ml) for each treatment group in EMT-6/V. Concentrations used were: baicalin 175 µM, EGCG 125 µM, baicalin and EGCG 140 and 100 µM respectively, vincristine 643 µg/ml, and positive control treated with MEM.

opencc-by-4.0Mar 2024View details →
zenodo28/100

Figure 10 from: Awajan D, Abu-Humaidan AHA, Talib WH (2024) Study of the antitumor activity of the combination baicalin and epigallocatechin gallate in a murine model of vincristine-resistant breast cancer. Pharmacia 71: 1-20. https://doi.org/10.3897/pharmacia.71.e113446

Figure 10 A plot of change in average tumor size (mm³) vs. time in (days) of treatment in the EMT-6/P cell line.

opencc-by-4.0Mar 2024View details →
zenodo28/100

Figure 16 from: Awajan D, Abu-Humaidan AHA, Talib WH (2024) Study of the antitumor activity of the combination baicalin and epigallocatechin gallate in a murine model of vincristine-resistant breast cancer. Pharmacia 71: 1-20. https://doi.org/10.3897/pharmacia.71.e113446

Figure 16 Effect of baicalin (75 mg/kg/day), EGCG (50 mg/kg/day), a combination of baicalin and EGCG (75 and 50 mg/kg/day) respectively, vincristine 2 mg/kg/every other day, combination with vincristine (75 and 50 mg/kg/day) for combination and (2 mg/kg/every other day) for vincristine, positive control (PBS and tween 20%), and healthy group on serum ALT level measured by (IU/L) in EMT-6/V.

opencc-by-4.0Mar 2024View details →
zenodo28/100

Figure 15 from: Awajan D, Abu-Humaidan AHA, Talib WH (2024) Study of the antitumor activity of the combination baicalin and epigallocatechin gallate in a murine model of vincristine-resistant breast cancer. Pharmacia 71: 1-20. https://doi.org/10.3897/pharmacia.71.e113446

Figure 15 Effect of baicalin (75 mg/kg/day), EGCG (50 mg/kg/day), a combination of baicalin and EGCG (75 and 50 mg/kg/day) respectively, vincristine 2 mg/kg/every other day, combination with vincristine (75 and 50 mg/kg/day) for combination and (2 mg/kg/every other day) for vincristine, positive control (PBS and tween 20%), and healthy group on serum ALT level measured by (IU/L) in EMT-6/P.

opencc-by-4.0Mar 2024View details →
zenodo28/100

Figure 11 from: Awajan D, Abu-Humaidan AHA, Talib WH (2024) Study of the antitumor activity of the combination baicalin and epigallocatechin gallate in a murine model of vincristine-resistant breast cancer. Pharmacia 71: 1-20. https://doi.org/10.3897/pharmacia.71.e113446

Figure 11 Tumor sizes in EMT-6/V after dissection at day 10 in all groups compared to each other, n = 7.

opencc-by-4.0Mar 2024View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record